Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

M. Lusher, Jeanne; Arkin, Steven; F. Abildgaard, Charles; S. Schwartz, Richard

doi:10.1056/nejm199302183280701

Public

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

Published in New England Journal of Medicine • Feb 18, 1993

Authors:

Jeanne M. Lusher

Steven Arkin

Charles F. Abildgaard

Abstract

BACKGROUND: Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat...

Subject

Medicine

Adverse effect

Clotting factor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!